Fennec reports Q2 EPS (20c), consensus (3c)

Reports Q2 revenue $7.26M, consensus $11.05M. Anticipates that cash, cash equivalents and investment securities as of June 30, 2024 of $43.1M will be sufficient to fund planned operations for at least the next twelve months. “We continued to execute well in the second quarter and are encouraged by the early third quarter momentum of PEDMARK(R) within the community oncology and the adolescent and young adult (AYA) population,” said Jeff Hackman, CEO. “I am excited to join Fennec and take on the challenge of guiding the Company towards greater commercial success. We will focus on expanding our initial outreach to community oncology centers and the adolescent and young adult (AYA) population, who can greatly benefit from our treatments. By reaching more patients in these critical areas, I am confident that we can drive growth and make a significant impact in improving patient outcomes.”